Recent Updates
Recently added Catalysts
BNGO

Bionano Genomics Announces Presentations on Optical Genome Mapping at the American Association for Cancer Research (AACR) Annual Meeting 2021

Key Takeaway: SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that multiple studies on the detection of structural variants using Bionano’s optical genome mapping, including a Spotlight Presentation, will be presented at the American Associat

Full Press Release Details

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that multiple studies on the detection of structural variants using Bionano’s optical genome mapping, including a Spotlight Presentation, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which is being held in a virtual format April 10-15, 2021.
Details of the presentations are as follows:
Title of Spotlight Presentation: “Optical Genome Mapping: Unrivaled Structural Variant Detection for Cancer Research and Precision Medicine” - Dr. Yannick Delpu, Bionano Genomics
“Optical Genome Mapping Uncovers Novel Structural Variants Associated With Drug Sensitivities In Leukemias” - Dr. Darren Finlay, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
Presentation Time: April 14, 2021, 1:00 - 2:00 PM EDT
Session Category: ESP.15
Title: Detection of Structural Variation and Analysis on HuKemia Models by Using Bionano Optical Mapping
Session Category: Molecular and Cellular Biology/Genetics
Session Title: Genomic Profiling of Tumors
Permanent Abstract Number: 2234
Authors: Xiaobo Chen, Huan Tian, Wubin Qian, Henry Q. Li, Sheng Guo. Crown Bioscience Inc, Suzhou, China, Crown Bioscience Inc, San Diego, CA
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
Bionano Genomics, Inc.
Investor Relations and
Last updated: Apr 7, 2021